PAREXEL and National Taiwan University Hospital Enter Partnership to Support Clinical Research in Taiwan
BOSTON and TAIPEI CITY, Taiwan, Nov. 27, 2012 /PRNewswire/ — PAREXEL International Corporation (NASDAQ: PRXL) a leading global biopharmaceutical services provider, and the National Taiwan University Hospital (NTUH) announced today that they have established an alliance. Under the agreement, PAREXEL and NTUH will collaborate to provide drug development services in Taiwan.
“Partnering with National Taiwan University Hospital further enhances our ability to meet the increasing demand from our clients to provide a full scope of Phase I-IV clinical trials in a rapidly growing market,” said Joe Avellone, M.D., Corporate Senior Vice President, Clinical Research Services, PAREXEL International. “The National Taiwan University Hospital is well-known and highly respected in Taiwan. We are pleased to have the opportunity to work together to advance our biopharmaceutical clients’ programs in the region and help them to compete more effectively in the global marketplace.”
“We are delighted to collaborate with PAREXEL, a world-leading biopharmaceutical services provider” said Ming-Fong Chen, M.D., Ph.D., Superintendent at National Taiwan University Hospital. “PAREXEL has a wealth of experience in both local and global clinical development programs. This partnership will bring opportunities for both PAREXEL and NTUH to leverage our combined expertise in order to accelerate clinical development programs in Taiwan and meet patients’ need for more effective treatments.”
The alliance will drive greater efficiency for biopharmaceutical sponsors worldwide. As a center of excellence for clinical trials in Taiwan and the Asia-Pacific region, the National Taiwan University Hospital is ideally positioned to support PAREXEL in delivering a superior clinical development service to local and global biopharmaceutical companies. The combined experience and development expertise of the two organizations will help to create innovative solutions for biopharmaceutical companies looking to develop or market their products within this important region.
About National Taiwan University Hospital (NTUH)
NTUH started operations in 1895. NTUH’s modern hospital was designed to support the concept of “patient-centered-care”, by which treatment is delivered at the bedside whenever possible. The hospital endeavors to provide appropriate, effective, and compassionate care that is accessible, affordable, and culturally sensitive, and in all these respects it serves as a model to emulate for other hospitals and clinics across the nation. With more than 4,000 employees serving approximately 2,000 inpatient beds, 7,000 daily outpatient visits, and over 200 chemotherapy treatments per day, NTUH remains the best-known and highest-quality academic medical center in Taiwan. For more information, please visit http://www.ntuh.gov.tw/en/default.aspx.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 13,330 employees. For more information about PAREXEL International visit www.parexel.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 as filed with the SEC on November 8, 2012, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
Contacts: Diana Martin, Vice President Corporate Communications Wing-Kai Chan, Director PAREXEL International National Center of Excellence for Clinical Trial & Research Tel: +1 781 434-5516 Tel:+886 2-3366-8246 Email: Diana.Martin@PAREXEL.com Email: firstname.lastname@example.org Kim Leadley PAN Communications Tel: +1 617-502-4300 Tel: +886 2-23123456 EXT.62020 Email: PAREXEL@pancomm.com Email: email@example.com
SOURCE PAREXEL International Corporation